New drug shows promise against rare skin cancer
NCT ID NCT04577755
First seen Sep 30, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This phase II trial tests the drug pomalidomide in about 45 people with Kaposi sarcoma, a rare skin cancer. Pomalidomide works by stopping blood vessel growth and boosting the immune system to fight cancer cells. The study aims to see how long tumors shrink and how many people respond to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Boston Medical Center
Boston, Massachusetts, 02118, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Miami Cancer Institute
Miami, Florida, 33176, United States
-
Montefiore Medical Center-Einstein Campus
The Bronx, New York, 10461, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107, United States
-
Thomas Street at Quentin Mease Health Center
Houston, Texas, 77004, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Illinois
Chicago, Illinois, 60612, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pomalidomide
What this could lead to
If it works, this could point toward a new treatment option for Kaposi sarcoma, helping to shrink tumors and control the disease.
What could go wrong
This is a small, early-phase trial with only 45 participants. The drug may not work for everyone, and side effects like low blood counts or fatigue are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.